Showing posts with label FDA Law Blog January 30. Show all posts
Showing posts with label FDA Law Blog January 30. Show all posts

Friday, January 31, 2014

FDA Law Blog January 30, 2014 An Old Fashioned Park Criminal Prosecution With Some Twists - Part II

By John R. Fleder
On October 2, 2013, HP&M posted the following on this blog:
On September 26, 2013, the United States Attorney for the District of Colorado announced that he had filed a six count criminal Information against Eric and Ryan Jensen.  The government alleges that the defendants violated the FDC Act by introducing adulterated cantaloupes into interstate commerce.  The government also alleges that the cantaloupes bore Listeria monocytogenes and 33 people died.  It is quite curious (we are being charitable here) that the government’s press release alleges that 147 people were hospitalized as a result of sales of the cantaloupes, but those allegations appear nowhere in the criminal Information!
continue to read here 

FDA Law Blog January 30, 2014 Speech by High-Level DOJ Official Claims Shared Interests of Prosecutors and Regulated Industry

By JP Ellison
In a speech on January 29th at the CBI Pharmaceutical Compliance Congress that DOJ posted on its own website, U.S. Department of Justice Assistant Attorney General Stuart Delery set forth his views of the three ways that the government’s enforcement interests align with industry’s interests.  While the speech didn’t break any new ground, it serves as a reminder that pharmaceutical enforcement cases remain a DOJ priority and suggests that recent enforcement trends will continue.
AAG Delery Claimed that DOJ and industry shared the following:
  1.  “[A] common interest in promoting ethical corporate culture instead of maintaining a compliance program in name only;”
  2. “Transparency about the conduct [the government] investigate[s];” and
  3. “[A] common interest in ensuring that corporate compliance is not only the right thing to do but also a winning business strategy.”
continue to read here